Showing 2271-2280 of 3315 results for "".
- Opus Genetics Expands its Leadership Teamhttps://modernod.com/news/opus-genetics-expands-its-leadership-team/2480981/Opus Genetics, a gene therapy company developing treatments for inherited retinal diseases, announced the appointments of Vikram Arora, PhD, DABT, as Vice President of Non-Clinical Development; Erin O’Neil, MD, as Vice President of Clinical Development; and Sarah Tuller, JD, RAC, as Vice Pr
- Global Data: Increasing Cataract Surgical Rates Will Drive Artificial Lenses Market to Reach $4.7 Billion by 2030https://modernod.com/news/global-data-increasing-cataract-surgical-rates-will-drive-artificial-lenses-market-to-reach-47-billion-by-2030/2480953/The global market for IOLs is forecast by GlobalData to steadily grow from $4.3 billion in 2021 to $4.7 billion by the end of the decade. The data and analytics company notes that this growth is primarily driven by the growing capacity of many hospitals and clinics across all regions to perform m
- Foundation Fighting Blindness Announces Leadership Changeshttps://modernod.com/news/foundation-fighting-blindness-announces-leadership-changes/2480924/The Foundation Fighting Blindness announced the promotions of Jason Menzo to chief executive officer of the Foundation, and Russell Kelley, PhD, MBA, to managing director of the Retinal Degeneration (RD) Fund, the venture arm of the Foundation, effective Ju
- New Study Shows Intraocular Lens Centration and Stability May Be Improved When Zepto Capsulotomy Platform is Used with Purkinje Reflectionshttps://modernod.com/news/new-study-shows-intraocular-lens-centration-and-stability-may-be-improved-when-zepto-capsulotomy-platform-is-used-with-purkinje-reflections/2480912/Centricity Vision announced the publication of a clinical study describing how to use Purkinje reflections at patient fixation for capsulotomy centration and 360-degree capsular overlap with the Zepto platform to help achieve improved visual outcomes. Published in the Journal
- CORE Study Shows Importance of Rub and Rinse Regimen for Coronavirus Removal from Contact Lens Materialshttps://modernod.com/news/core-study-shows-importance-of-rub-and-rinse-regimen-for-coronavirus-removal-from-contact-lens-materials/2480905/A new study conducted by the
- Horizon Therapeutics Launches Letter-Writing Campaign to Empower Those Living with Thyroid Eye Disease (TED) to Confront the Condition Head Onhttps://modernod.com/news/horizon-therapeutics-launches-letter-writing-campaign-to-empower-those-living-with-thyroid-eye-disease-ted-to-confront-the-condition-head-on/2480860/For Mental Health Awareness Month and Healthy Vision Month in May, Horizon Therapeutics is partnering with mental health expert and New York Times best-selling author, Lori Gottlieb, to highlight the emotional burden of living with TED—a serious, progressive, and poten
- Kala Pharmaceuticals Launches Its First Direct-to-Consumer Campaign to Increase Awareness of Dry Eye Flareshttps://modernod.com/news/kala-pharmaceuticals-launches-its-first-direct-to-consumer-campaign-to-increase-awareness-of-dry-eye-flares/2480850/Kala Pharmaceuticals, Inc. today announced the launch of its first direct-to-consumer (DTC) campaign, “There for the Flare.” The campaign leverages digital channels to educate patients about dry eye flares and EYSUVIS® (loteprednol etabonate ophthalmic suspension 0.25%) and encour
- SightGlass Vision Presents 24-Month Data Demonstrating Myopia Control Efficacy for Vision Spectacle Lenseshttps://modernod.com/news/sightglass-vision-presents-24-month-data-demonstrating-myopia-control-efficacy-for-vision-spectacle-lenses/2480823/Spectacles that use SightGlass Vision Diffusion Optics Technology have demonstrated efficacy in slowing the progression of myopia in children,[1] based on 24-month interim data from its pivotal c
- Shamir Announces Changes in Executive Leadershiphttps://modernod.com/news/shamir-announces-changes-in-executive-leadership/2480772/Shamir Insight announced that effective April 1, 2022, Pierson Ball, the company’s Director of Business and Strategic Development has been appointed as the new Vice President of Sales. Mr. Ball joined Shamir in 2007. “I am proud to have been part of the development and
- Apellis' Pegcetacoplan Showed Continuous Effects at Month 18 in Phase 3 DERBY and OAKS Studies for Geographic Atrophy (GA)https://modernod.com/news/apellis-announces-pegcetacoplan-showed-continuous-and-clinically-meaningful-effects-at-month-18-in-phase-3-derby-and-oaks-studies-for-geographic-atrophy-ga/2480701/Apellis Pharmaceuticals announced longer-term data from the phase 3 DERBY and OAKS studies, which showed that intravitreal pegcetacoplan, an investigational, targeted C3 therapy, continued to reduce geographic atrophy (GA) lesion growth and demonstrate a favorable safety profile at month 18 for t